COVID-19 testing

It's 2023: Where is the At-Home IVD Testing Market Now?

Retrieved on: 
Thursday, June 15, 2023
Insurance, Telehealth, Pregnancy, HIV, Internet, Glucose, COVID-19, Infection, FOB, COVID-19 testing, Home, IVD, Medical device, Pharmaceutical industry

ARLINGTON, Va., June 15, 2023 /PRNewswire-PRWeb/ -- The Home in vitro diagnostic (IVD) testing market is not new, but it had primarily been limited to glucose and pregnancy testing. COVID-19 testing has opened the door for home infectious disease testing and more. The market is detailed in "At-Home Diagnostic Testing Markets and Trends (COVID-19, FOB, Glucose, HIV and Other Tests), 2023", the latest report published by leading medical market research firm Kalorama Information.

Key Points: 
  • ARLINGTON, Va., June 15, 2023 /PRNewswire-PRWeb/ -- The Home in vitro diagnostic (IVD) testing market is not new, but it had primarily been limited to glucose and pregnancy testing.
  • The global Home IVD testing market was valued at $28.9 billion in 2022, with the largest portion of that attributed to glucose testing and COVID-19 testing.
  • The Home IVD market increased 9% over 2021, largely due to increases in the infectious disease segment, namely COVID-19 testing sales.
  • The Home IVD testing market is a growing market facilitated by the proliferation of COVID-19 tests that have entered the market since the pandemic began.

Curative Expands No Copay, No Deductible Health Insurance Plan to Houston Metro Area

Retrieved on: 
Monday, June 12, 2023
Health Insurance, Telemedicine, Virtual Medicine, Insurance, Pharmaceutical, Professional Services, Mental Health, General Health, Women, Seniors, Hospitals, Fitness & Nutrition, Men, Family, Consumer, Health, Telehealth, Food, PPO, COVID-19, OOP, Clothing, RIM, Prescription, COVID-19 testing, Plasma protein binding, Census, Hospital, Patient, Ageing, Health insurance, Curative

Curative Insurance Company , provider of a cutting-edge, no copay, no deductible health plan*, is now expanding its fully insured benefit offering to the Houston metro area to serve employers in all of Harris County as well as any of their employees nationwide.

Key Points: 
  • Curative Insurance Company , provider of a cutting-edge, no copay, no deductible health plan*, is now expanding its fully insured benefit offering to the Houston metro area to serve employers in all of Harris County as well as any of their employees nationwide.
  • Curative now has one of the largest provider networks in the Houston area as well as a broad nationwide network of providers to support its unique solution.
  • Curative Insurance Company recently commissioned this survey of Houstonians enrolled in employer-sponsored insurance plans** to understand how healthcare costs affect their choices in seeking care.
  • Curative’s health plan eliminates the financial barriers for patients accessing health insurance by offering no-cost services for in-network care with the completion of a baseline visit.

Chronus Health Appoints Dr. Ajit Singh as Chairman of the Board of Directors

Retrieved on: 
Thursday, June 8, 2023
Columbia University, Conditional sentence, Bachelor, Executive, AACR, Max Healthcare, The Washington Campus Board of Directors, Senior advisor, Roche, COVID-19, Cancer, Ageing, Stanford University, COVID-19 testing, Computer, Sir Ratan Tata Trust, Organization, Silicon, Syracuse University, Book, Entrepreneurship, Partner, Trustee, School, Master, Knowledge, Computer science, Banaras Hindu University, Electricity, Virginia Tech Carilion School of Medicine and Research Institute, Medical device, Management, Medicine

FREMONT, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Chronus Health, Inc. , a disruptor in point-of-care diagnostics, today announced it has appointed Dr. Ajit Singh as Chairman of the company's Board of Directors.

Key Points: 
  • FREMONT, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Chronus Health, Inc. , a disruptor in point-of-care diagnostics, today announced it has appointed Dr. Ajit Singh as Chairman of the company's Board of Directors.
  • Dr. Singh is currently a Partner at Artiman Ventures, a Silicon Valley-based venture capital firm, serving on the Board of Directors of several life sciences and healthcare portfolio companies.
  • He is also an Adjunct Professor in the School of Medicine at Stanford, where he teaches diagnostics and entrepreneurship.
  • In addition, he is a member of the Board of Trustees of the American Association for Cancer Research (AACR) Foundation.

 Novir Announces the Evolution of Their Business to a More Comprehensive Healthcare Solutions Provider Focused on Advancing the Pre-Care Pathway

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, General Health, Health Technology, Health, COVID-19, Vaccination, COVID-19 testing, Pharmaceutical industry

Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime.

Key Points: 
  • Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime.
  • Since their inception in 2020 amidst the pandemic, Novir worked to provide over 600,000 life-saving screenings or vaccinations across the US.
  • "Our team has worked tirelessly to create an easy-to-use platform that provides the latest information and resources to help prevent illnesses and promote health."
  • Novir’s new website offers a wide range of information and resources about their customers served as well as Novir’s comprehensive healthcare solutions portfolio including:
    To learn more about Novir, visit Novir-usa.com

Bicycle Health Appoints Amy Finney as New Chief Operating Officer

Retrieved on: 
Wednesday, May 31, 2023
Insurance, 1Life Healthcare, University, The BMJ, Medical journal, Policy, COVID-19, Opioid use disorder, Health, Business, OUD, University of California, MBA, Finney, COVID-19 testing, Addiction medicine, Heart, Business administration, Journal, Incident response team, Patient, Pharmaceutical industry, Operation

BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Bicycle Health , the leading telehealth provider of integrated medical and behavioral health care for opioid use disorder (OUD) in the United States, today welcomed Amy Finney as its new Chief Operating Officer (COO).

Key Points: 
  • BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Bicycle Health , the leading telehealth provider of integrated medical and behavioral health care for opioid use disorder (OUD) in the United States, today welcomed Amy Finney as its new Chief Operating Officer (COO).
  • Finney brings extensive experience in healthcare operations and leadership to the Bicycle Health team, where she will continue the company’s momentum and ensure that patients struggling with OUD can access Bicycle Health’s life-saving treatment.
  • Finney joins Bicycle Health from One Medical, where she most recently served as the Vice President of Operations.
  • “We are welcoming Amy to our leadership team at a major inflection point for Bicycle Health,” said Ankit Gupta, CEO and founder of the company.

MCI Onehealth Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 16, 2023
Lincolnshire Co-operative Challenge, NOT, FOR, Face, Toronto Stock Exchange, Bank statement, COVID-19, Record, Research, MCI, COVID-19 testing, Sale, Practitioner, WIRE, EBITDA, Patient, Physician, Data, Health, NEWS, TSX, News, Pharmaceutical industry, Risk management, Nursing

TORONTO, May 15, 2023 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. (“MCI” or the “Company”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, has released its financial results for the three months ended March 31, 2023.

Key Points: 
  • NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
    TORONTO, May 15, 2023 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. (“MCI” or the “Company”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, has released its financial results for the three months ended March 31, 2023.
  • Financial measures described as “Adjusted” in this news release are non-IFRS financial measures and may not be comparable to other similar measures disclosed by other companies.
  • The Company provided an update on these efforts, which are ongoing, in a press release on April 20, 2023.
  • Personnel: The Company hired 8 new physicians during the three months ended March 31, 2023, who will begin delivering health services to patients in 2023.

Progressive Care Inc. Announces First Quarter 2023 Financial Results and Record Quarterly Revenues of $11.4 Million

Retrieved on: 
Friday, May 12, 2023
PBM, COVID-19, Three Months, Pharmacy, COVID-19 testing

Financial Results for the Three Months Ended March 31, 2023

Key Points: 
  • Financial Results for the Three Months Ended March 31, 2023
    For the three months ended March 31, 2023 and 2022, we recognized overall revenue from operations of approximately $11.4 million and $10.1 million, respectively.
  • Net pharmacy revenues increased by approximately $1.3 million during the three months ended March 31, 2023 when compared to the same period in 2022.
  • Gross profit margins increased from 24% for the three months ended March 31, 2022, to 28% for the three months ended March 31, 2023.
  • We had a net loss of approximately $0.1 million and $1.4 million for the three months ended March 31, 2023 and 2022, respectively.

Biodesix Announces First Quarter 2023 Results and Highlights

Retrieved on: 
Thursday, May 11, 2023
Software, Research, General Health, Oncology, Medical Devices, Technology, Infectious Diseases, Artificial Intelligence, Health Technology, Science, Biotechnology, Health, Marketing, COVID-19, COVID-19 testing, Webcast, Growth, Pharmaceutical industry, Cryptocurrency

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2023 and provided a corporate update.
  • “Throughout the quarter we continued to make excellent progress and I am pleased with the start to the year.
  • Looking at our financial performance, we reported total revenue of $9.1 million for the first quarter 2023, which represents growth of 38% compared to the first quarter of 2022, while core lung diagnostic revenue of $8.6 million grew by 86% over the comparable period,” said Scott Hutton, President and Chief Executive Officer.
  • The Company reaffirms our 2023 financial outlook and expects to generate between $52 million and $55 million in total revenue in 2023.

Biocept Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Biotechnology, Health, Clinical Trials, Health Technology, Oncology, Marketing, COVID-19, Negotiation, COVID-19 testing, San Francisco Bay Area, Neuro, Research, Pharmaceutical industry, Video game

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update.

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update.
  • General and administrative expenses for the first quarter of 2023 were $3.0 million, compared with $6.3 million for the first quarter of 2022.
  • The decrease was primarily due to lower legal and outside service expenses in the 2023 quarter, and separation agreements with former executive management in the 2022 quarter.
  • Biocept reported cash of $6.8 million as of March 31, 2023, compared with $12.9 million as of December 31, 2022.

EQS-News: SYNLAB AG: SYNLAB reports strong start to fiscal year 2023

Retrieved on: 
Wednesday, May 10, 2023
Omicron, EV, FY, Stock dilution, COVID-19, D2C, EDT, COVID-19 testing, EBITDA, Acquisition, CEST, AOP, Growth, Environment, Mobile phone, Renewable energy, Pharmaceutical industry, AEBITDA

However, Q1 2023 revenue was at the same level as prior-quarter revenue (Q4 2022: €701 million) despite lower COVID-19 testing volumes (Q4 2022: €70 million).

Key Points: 
  • However, Q1 2023 revenue was at the same level as prior-quarter revenue (Q4 2022: €701 million) despite lower COVID-19 testing volumes (Q4 2022: €70 million).
  • Q1 2023 had more working days overall than Q1 2022, and SYNLAB achieved record daily revenues of €10 million with over-delivery of the Group’s For You Growth Initiatives.
  • SYNLAB completed three bolt-on acquisitions in Q1 2023 with an accumulated EV of €23 million.
  • SYNLAB held €396 million in cash at the end of Q1 2023 (year-end 2022: €542 million) as the Group repaid €100 million gross debt in February 2023.